2025 Annual Meeting | C189 - Alzheimer's Disease
03:30 PM - 04:30 PM PDT | Introduction |
Welcome and Introductions
Liliana A. Ramirez-Gomez, MD |
03:36 PM - 04:10 PM PDT | Speaker |
The use of biomarkers for the diagnosis and staging of Alzheimer’s disease
Julio C. Rojas-Martinez, MD, PhD |
04:11 PM - 04:40 PM PDT | Speaker |
Emerging Therapies for the Treatment of Alzheimer’s Disease
Jeremy J. Pruzin, MD |
04:41 PM - 05:10 PM PDT | Speaker |
Implementation of newly approved disease-modifying therapies for Alzheimer’s Disease in clinical practice
Liliana A. Ramirez-Gomez, MD |
05:11 PM - 05:30 PM PDT | Q&A |
Questions and Answers
Liliana A. Ramirez-Gomez, MD, Jeremy J. Pruzin, MD, Julio C. Rojas-Martinez, MD, PhD |
Liliana A. Ramirez-Gomez, MD | The institution of Dr. Ramirez-Gomez has received research support from NIA-NIH. |
Jeremy J. Pruzin, MD | Dr. Pruzin has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eisai. Dr. Pruzin has received personal compensation in the range of $500-$4,999 for serving as a Consultant for MedNet. Dr. Pruzin has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Synapticure. The institution of Dr. Pruzin has received research support from Alzheimer's Association. The institution of Dr. Pruzin has received research support from NIA. |
Julio C. Rojas-Martinez, MD, PhD | The institution of Dr. Rojas-Martinez has received research support from NIH/NIA. The institution of Dr. Rojas-Martinez has received research support from Eli Lilly. The institution of Dr. Rojas-Martinez has received research support from Eisai. Dr. Rojas-Martinez has received research support from Roon, Healthcare. The institution of Dr. Rojas-Martinez has received research support from Amylyx. |